News
SVRA
--
0.00%
--
Hot Penny Stocks To Watch Today But Is It Time To Buy The Dip?
Feb 24, 2021 (Penny Stocks via COMTEX) -- Penny Stocks Are Trading Higher After Market-Wide Dip We talk about the relation of penny stocks to broader...
Penny Stocks · 02/24 21:12
Wednesday 2/24 Insider Buying Report: GTYH, SVRA
MarketNewsVideo.com · 02/24 18:38
Vascular Biogenics, Sunesis Pharmaceuticals leads healthcare gainers; Isoray, Vaccine among major losers
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed PAVM -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics ONTX -15%, electroCore (ECOR) -14%.
Seekingalpha · 02/23 16:03
Is the Options Market Predicting a Spike in Savara (SVRA) Stock?
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Zacks · 02/05 13:32
Is the Options Market Predicting a Spike in Savara (SVRA) Stock?
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Zacks · 02/05 13:32
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Simply Wall St. · 01/21 09:24
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 01/21 09:24
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Simply Wall St. · 01/21 09:24
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Simply Wall St. · 01/21 09:24
8-K: Savara Inc
(EDGAR Online via COMTEX) -- Savara Inc false 0001160308 0001160308 2021-01-15 2021-01-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/20 04:48
Is SVRA A Good Stock To Buy Now?
Insider Monkey · 12/10/2020 17:02
Is SVRA A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of...
Insider Monkey · 12/10/2020 17:02
Is SVRA A Good Stock To Buy Now?
Insider Monkey · 12/10/2020 17:02
Immutep, Greenwich LifeSciences leads healthcare gainers; Xenetic Biosciences, Oncternal Therapeutics among major losers
Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax Labs (GOVX) -26%, Genetic Technologies (GENE) -20%, Savara (SVRA) -10%.
Seekingalpha · 12/10/2020 16:00
Savara's AeroVanc flunks in late-stage study in cystic fibrosis with MRSA infection, development discontinued
Savara (SVRA) plummets 26% in premarket in reaction to topline data from the Phase 3 AVAIL study evaluating AeroVanc (vancomycin hydrochloride inhalation powder) in cystic fibrosis patients with methicillin-resistant Staphylococcus aureus ((MRSA))
Seekingalpha · 12/10/2020 13:59
Savara Provides Pipeline And Business Update; Co. Discontinues Development Of Apulmiq Program, Focuses Resources On Molgradex In aPAP, Reduces Operating Expenses 'to Align with Streamlined Development Programs'
Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses
Benzinga · 12/10/2020 13:10
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPA...
Business Wire · 12/10/2020 13:05
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPA...
Business Wire · 12/10/2020 13:05
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPA...
Business Wire · 12/10/2020 13:05
Savara Provides Pipeline and Business Update
--Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO
BusinessWire · 12/10/2020 10:05
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.